Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
Open Posted
- Opportunity number
- PAR-28-014
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.113 Environmental Health
- 93.393 Cancer Cause and Prevention Research
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- 501(c)(3) Nonprofits
- Other
- Independent School Districts
- County Governments
- Non-501(c)(3) Nonprofits
- State Governments
- For Profit Organizations
- Tribal Governments (Federally Recognized)
- Higher Education Inst. (Private)
- Tribal Organizations (Not Federally Recognized)
- Higher Education Inst. (Public)
- Public or Indian Housing Auth.
- Small Businesses
- City/Township Governments
- Special District Governments
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute (NCI) and National Institute of Environmental Health Sciences (NIEHS) seek applicants to investigate the etiology, biological mechanisms, and early detection strategies for sporadic non-hereditary early-onset cancers in adults aged 18–49 years, with applications due by 5:00 PM local time on October 11, 2029 (rolling submission cycles).
Eligible applicants include 501(c)(3) and non-501(c)(3) nonprofits, higher education institutions (public and private), for-profit organizations, state and local governments, tribal governments (federally recognized and non-federally recognized), U.S. territories, regional organizations, and foreign organizations (with restrictions: foreign subawards and subcontracts are prohibited; unfunded international collaborations and foreign consultants are permitted). All applicants must register with SAM, obtain a UEI, establish eRA Commons accounts, and register with ORCID.
No cost share is required. Two application tracks operate with distinct budgets and timelines: exploratory/developmental research projects (up to 3 years, $200,000 maximum direct costs annually, 6-page limit) and standard research projects (up to 5 years, $500,000 maximum direct costs annually, 12-page limit). The NOFO does not specify an expected number of awards.
Research must address one or more of three priority areas: identifying environmental or lifestyle exposures driving increased early-onset cancer incidence and demographic variation; examining biological mechanisms and host responses underlying early-onset cancers; or developing effective methods to identify patients at increased risk. Focus areas include understudied cancers with rising incidence trends in young adults, including early-onset uterine, pancreatic, and kidney cancers; early-onset colorectal and breast cancer applications are also considered.
Peer review assesses significance, innovation, rigor, feasibility, and investigator expertise. Applications undergo two-level review: initial scientific merit evaluation by a peer review panel, followed by advisory council review. The combined review and funding decision process takes approximately 10 months from submission. Applications must include a Data Management and Sharing Plan and comply with NIH Grants Policy Statement requirements.
The opportunity is assigned to Cancer Cause and Prevention Research (CFDA 93.393) and Environmental Health (CFDA 93.113).
Synopsis
This Notice of Funding Opportunity (NOFO) invites applications that investigate the etiology of sporadic non-hereditary early-onset cancers (EOCs: ages 18 to 49 years) and the underlying biological mechanisms that play a role in these cancers to inform prevention and control strategies. The proposed research is expected to advance the understanding of the unexplained rise of cancers in young adults. More specifically, studies should focus on one or more of the following: i) identifying what environmental or lifestyle exposures are driving the increase in the incidence of non-hereditary EOCs, and how these factors vary by patient demographics; ii) examining the biological mechanisms and host responses that underlie the increase in EOCs; and iii) identifying how those at increased risk of developing EOCs can be identified more effectively.
In an effort to streamline the application process and sustain momentum in this critical research area, this NOFO supports both exploratory/developmental and standard research projects through a grant award instrument.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Files
| File | Type | Posted |
|---|---|---|
| PKG00294377.pdf | ||
| PAR-28-014-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity